VC firms back $58m series-E for Immatics

The Dievini Hopp Biotech holding, Wellington Partners, AT Impf and Amgen all invested in the round.

The fresh capital will be used to progress the company's pipeline of adpotive cell therapies into clinical trials.

The company has raised a total of €191m over seven rounds, according to unquote" data.

Previous funding
In February 2004, Wellington led a consortium comprising 3i Group, Grazia Equity L-EA Private Equity and Merfin Capital to provide Immatics with a €7.75m investment. It was reported at the time as the largest initial round of funding for a German biotech company since 2002.

In July 2005, the previous investors were joined by Renaissance Capital in an additional €5.8m financing. 3i, Wellington and KfW then took part in a €40m round led by Dietmar Hopp's DH Capital in January 2007. The National Technology Enterprises Company of Kuwait also participated.

Specialist life sciences investor MIG then led a €53.8m series-C round in September 2010. Wellington, Dievini Hopp and AT Impf also invested.

MIG led the €12m series-D round in October 2013 alongside other previous investors, including Wellington and AT Impf. Finally, the series-D added another €22m tranche with backing from Dievini Hopp and Wellington in July 2014.

Company
Established in 2000, Immatics is a biopharmaceutical company that focuses on the development of new immunotherapeutic substances for cancer therapies. The company is based in Tuebingen, Germany and employs 100 people.

People
Immatics – Peter Chambré (chairman).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Wellington Partners